Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Exelixis Site #14, New York

Exelixis Site #15, The Bronx

Exelixis Clinical Site #3, New Hyde Park

Exelixis Site #13, Shirley

Exelixis Clinical Site #1, Orlando

Exelixis Site #9, Miami

Exelixis Site #11, Tampa

Exelixis Clinical Site #2, Nashville

Exelixis Site #12, Madison

Exelixis Site #5, St Louis

Exelixis Clinical Site #16, Salt Lake City

Exelixis Site #8, Los Angeles

Exelixis Site #4, Spokane

Exelixis Site #6, Scarborough